6,978 Shares in Masimo Corporation $MASI Bought by Versor Investments LP

Key Points

• Versor Investments LP has invested approximately $1.16 million in Masimo Corporation by purchasing 6,978 shares during the first quarter.
• Analysts have mixed ratings on Masimo, with BTIG Research maintaining a "buy" rating, while other firms like Wells Fargo have lowered their price targets.
• Masimo's recent earnings report revealed an EPS of $1.33, surpassing expectations and showing a 7.7% increase in quarterly revenue year-over-year.

Versor Investments LP acquired a new stake in shares of Masimo Corporation (NASDAQ:MASI - Free Report) during the first quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund acquired 6,978 shares of the medical equipment provider's stock, valued at approximately $1,163,000.

A number of other institutional investors and hedge funds have also modified their holdings of MASI. LPL Financial LLC increased its position in shares of Masimo by 22.9% during the fourth quarter. LPL Financial LLC now owns 4,310 shares of the medical equipment provider's stock valued at $712,000 after purchasing an additional 803 shares during the period. Envestnet Asset Management Inc. boosted its stake in Masimo by 17.3% in the 4th quarter. Envestnet Asset Management Inc. now owns 31,107 shares of the medical equipment provider's stock valued at $5,142,000 after buying an additional 4,579 shares in the last quarter. Barclays PLC boosted its stake in Masimo by 33.2% in the 4th quarter. Barclays PLC now owns 53,219 shares of the medical equipment provider's stock valued at $8,796,000 after buying an additional 13,262 shares in the last quarter. Mariner LLC boosted its stake in Masimo by 10.2% in the 4th quarter. Mariner LLC now owns 3,459 shares of the medical equipment provider's stock valued at $572,000 after buying an additional 321 shares in the last quarter. Finally, Guggenheim Capital LLC boosted its stake in Masimo by 61.5% in the 4th quarter. Guggenheim Capital LLC now owns 7,021 shares of the medical equipment provider's stock valued at $1,161,000 after buying an additional 2,674 shares in the last quarter. 85.96% of the stock is currently owned by institutional investors.

Insider Activity

In related news, Director William R. Jellison purchased 3,000 shares of Masimo stock in a transaction dated Monday, August 11th. The shares were acquired at an average cost of $145.98 per share, for a total transaction of $437,940.00. Following the transaction, the director directly owned 4,790 shares of the company's stock, valued at approximately $699,244.20. This trade represents a 167.60% increase in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this link. 9.70% of the stock is owned by corporate insiders.

Masimo Trading Up 3.0%

Shares of NASDAQ MASI traded up $4.39 during midday trading on Friday, hitting $148.63. The stock had a trading volume of 429,926 shares, compared to its average volume of 634,946. The company's 50-day simple moving average is $159.45 and its 200 day simple moving average is $163.17. The firm has a market cap of $8.08 billion, a P/E ratio of -17.44 and a beta of 1.21. Masimo Corporation has a fifty-two week low of $107.98 and a fifty-two week high of $194.88. The company has a debt-to-equity ratio of 0.57, a current ratio of 2.14 and a quick ratio of 1.61.

Masimo (NASDAQ:MASI - Get Free Report) last issued its earnings results on Tuesday, August 5th. The medical equipment provider reported $1.33 EPS for the quarter, beating the consensus estimate of $1.22 by $0.11. Masimo had a negative net margin of 24.85% and a positive return on equity of 26.54%. The company had revenue of $370.90 million during the quarter, compared to analysts' expectations of $368.65 million. During the same quarter in the previous year, the company posted $0.86 EPS. The business's revenue for the quarter was up 7.7% compared to the same quarter last year. Research analysts anticipate that Masimo Corporation will post 4.1 EPS for the current year.

Wall Street Analysts Forecast Growth

Several analysts recently commented on MASI shares. Piper Sandler boosted their price target on Masimo from $200.00 to $210.00 and gave the company an "overweight" rating in a research note on Wednesday, August 6th. Wall Street Zen lowered Masimo from a "buy" rating to a "hold" rating in a research note on Friday, May 30th. BTIG Research reiterated a "buy" rating on shares of Masimo in a research report on Thursday, August 14th. Wells Fargo & Company cut their price objective on Masimo from $205.00 to $190.00 and set an "overweight" rating for the company in a research report on Wednesday, May 7th. Finally, Raymond James Financial cut their price objective on Masimo from $204.00 to $185.00 and set an "outperform" rating for the company in a research report on Wednesday, May 7th. Five research analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the company's stock. According to MarketBeat, the stock has a consensus rating of "Moderate Buy" and a consensus price target of $193.60.

Masimo Profile

Masimo Corporation develops, manufactures, and markets various patient monitoring technologies, and automation and connectivity solutions worldwide. The company offers masimo signal extraction technology (SET) pulse oximetry with measure-through motion and low perfusion pulse oximetry monitoring to address the primary limitations of conventional pulse oximetry; Masimo rainbow SET platform, including rainbow SET Pulse CO-Oximetry products that allows noninvasive monitoring of carboxyhemoglobin, methemoglobin, hemoglobin concentration, fractional arterial oxygen saturation, oxygen content, pleth variability index, rainbow pleth variability index, respiration rate from the pleth, and oxygen reserve index, as well as acoustic respiration monitoring, SedLine brain function monitoring, NomoLine capnography and gas monitoring, and regional oximetry.